Report Sections

See All Reports

  • HP:0000822: Hypertension
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0000822: Hypertension

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (33)


    Name (Synonyms) Correlation
    drug2230 Nutritional support system (NSS) Wiki 0.24
    drug3320 The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki 0.24
    drug71 ACEI/ARB Wiki 0.24
    Name (Synonyms) Correlation
    drug709 Cenicriviroc (CVC) Wiki 0.24
    drug2359 PWV Wiki 0.24
    drug668 Calcium Channel Blockers Wiki 0.24
    drug2820 Reverse-transcription polymerase chain reaction (RT-PCR) Wiki 0.24
    drug2341 PLACEBO GROUP Wiki 0.24
    drug272 Artemisia Annua Leaf Wiki 0.24
    drug2192 Non-ACEI/ARB Wiki 0.24
    drug223 Angiotensin receptor blocker Wiki 0.24
    drug3767 echocardiogram 2D Wiki 0.24
    drug1490 Hydroxychloroquine Pre-Exposure Prophylaxis Wiki 0.24
    drug1242 FMD Wiki 0.24
    drug3188 Stress and emotion management Wiki 0.24
    drug70 ACEI Wiki 0.24
    drug731 Chest computed tomography (CT) Wiki 0.24
    drug2750 Rarefaction Wiki 0.24
    drug3345 Thiazide or Thiazide-like diuretics Wiki 0.24
    drug201 Amlodipine Wiki 0.24
    drug357 BCG GROUP Wiki 0.24
    drug1112 EXTRA-CVD Virtual Care Wiki 0.24
    drug65 ABPM Wiki 0.24
    drug222 Angiotensin converting enzyme inhibitor Wiki 0.17
    drug90 ARB Wiki 0.17
    drug1086 ECG Wiki 0.17
    drug767 Clinical data Wiki 0.14
    drug68 ACE inhibitor Wiki 0.14
    drug672 Camostat Mesilate Wiki 0.08
    drug2699 Questionnaires Wiki 0.08
    drug849 Control Wiki 0.07
    drug2514 Placebo oral tablet Wiki 0.04
    drug2448 Placebo Wiki 0.01

    Correlated MeSH Terms (23)


    Name (Synonyms) Correlation
    D006973 Hypertension NIH 1.00
    D006976 Hypertension, Pulmonary NIH 0.27
    D009080 Mucocutaneous Lymph Node Syndrome NIH 0.24
    Name (Synonyms) Correlation
    D001997 Bronchopulmonary Dysplasia NIH 0.24
    D008595 Menorrhagia NIH 0.24
    D006929 Hyperaldosteronism NIH 0.24
    D014552 Urinary Tract Infections NIH 0.24
    D054559 Hyperphosphatemia NIH 0.24
    D004314 Down Syndrome NIH 0.24
    D000309 Adrenal Insufficiency NIH 0.24
    D007008 Hypokalemia NIH 0.24
    D001289 Attention Deficit Disorder with Hyperactivity NIH 0.14
    D006470 Hemorrhage NIH 0.14
    D002318 Cardiovascular Diseases NIH 0.08
    D020141 Hemostatic Disorders NIH 0.06
    D001778 Blood Coagulation Disorders NIH 0.06
    D004194 Disease NIH 0.05
    D013315 Stress, Psychological NIH 0.04
    D013577 Syndrome NIH 0.02
    D003141 Communicable Diseases NIH 0.02
    D018352 Coronavirus Infections NIH 0.02
    D007239 Infection NIH 0.01
    D045169 Severe Acute Respiratory Syndrome NIH 0.01

    Correlated HPO Terms (9)


    Name (Synonyms) Correlation
    HP:0002092 Pulmonary arterial hypertension HPO 0.27
    HP:0002905 Hyperphosphatemia HPO 0.24
    HP:0002900 Hypokalemia HPO 0.24
    Name (Synonyms) Correlation
    HP:0000846 Adrenal insufficiency HPO 0.24
    HP:0000132 Menorrhagia HPO 0.24
    HP:0000859 Hyperaldosteronism HPO 0.24
    HP:0007018 Attention deficit hyperactivity disorder HPO 0.14
    HP:0001626 Abnormality of the cardiovascular system HPO 0.08
    HP:0001928 Abnormality of coagulation HPO 0.06

    Clinical Trials

    Navigate: Correlations   HPO

    There are 18 clinical trials


    1 Prognostic Characteristics Difference Between the Hypertension Patients With and Without ACEI Treatment When Suffered With 2019-nCoV Infection in China

    There are currently no clinical studies reporting clinical characteristics difference between the hypertension patients with and without ACEI treatment when suffered with novel coronavirus infection in China.

    NCT04272710
    Conditions
    1. 2019-nCoV
    MeSH:Hypertension
    HPO:Hypertension

    Primary Outcomes

    Description: The percentage of patients admitted to the ICU at any time during the 28 days of onset COVID-19.

    Measure: Occupancy rate in the intensive care unit (ICU)

    Time: up to 28 days

    Description: The number of patients requiring mechanical ventilation.

    Measure: Mechanical Ventilation

    Time: up to 28 days

    Description: The number of patients who died of 2019-nCoV infection.

    Measure: Death

    Time: up to 28 days

    Secondary Outcomes

    Description: The number of died 2019-nCoV infected patients from any cause.

    Measure: All cause mortality

    Time: up to 28 days

    Description: Time from onset of symptoms to admitted to the ICU, requiring mechanical ventilation, and death.

    Measure: Time from onset of symptoms to main outcome and its components

    Time: up to 28 days

    Description: Time to Clinical Recovery

    Measure: Time to Clinical Recovery

    Time: up to 28 days
    2 Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs

    The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

    NCT04278404
    Conditions
    1. Coronavirus Infection (COVID-19)
    2. Pulmonary Arterial Hypertension
    3. Urinary Tract Infections in Children
    4. Hypertension
    5. Pain
    6. Hyperphosphatemia
    7. Primary Hyperaldosteronism
    8. Edema
    9. Hypokalemia
    10. Heart Failure
    11. Hemophilia
    12. Menorrhagia
    13. Insomnia
    14. Pneumonia
    15. Skin Infection
    16. Arrythmia
    17. Asthma in Children
    18. Bronchopulmonary Dysplasia
    19. Adrenal Insufficiency
    20. Fibrinolysis; Hemorrhage
    21. Attention Deficit Hyperactivity Disorder
    22. Multisystem Inflammatory Syndrome in Children (MIS-C)
    23. Kawasaki Disease
    24. Coagulation Disorder
    25. Down Syndrome
    Interventions
    1. Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    MeSH:Infection Communicable Diseases Urinary Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome Bronchopulmonary Dysplasia Down Syndrome Menorrhagia Hypertension Hemostatic Disorders Mucocutaneous Lymph Node Syndrome Blood Coagulation Disorders Hyperphosphatemia Hypokalemia Adrenal Insufficiency Hyperaldosteronism Disease Syndrome Hemorrhage Attention Deficit Disorder with Hyperactivity
    HPO:Abnormality of coagulation Abnormality of the coagulation cascade Adrenal insufficiency Attention deficit hyperactivity disorder Hyperaldosteronism Hyperphosphatemia Hypertension Hypokalemia Menorrhagia Primary hyperaldosteronism

    Primary Outcomes

    Measure: Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Elimination rate constant (ke) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Half-life (t1/2) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Absorption rate constant (ka) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: AUC (area under the curve) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Maximum concentration (Cmax) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Time to achieve maximum concentration (Tmax) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
    3 Hypertension in Patients Hospitalized With COVID-19 in Wuhan, China: A Single-center Retrospective Observational Study

    Some studies have shown that the main pathogenesis of patients with covid19 is related to ACE2 receptor. Lung is one of the main organs, and there are many ACE2 receptors in cardiovascular system. ACEI / ARB is the main target of antihypertensive drugs. Previous reports suggested that there were large number of patients with covid19 also suffered from hypertension, suggesting that patients with hypertension may be the susceptible to covid19. Therefore, we try to follow up the patients admitted to Hankou hospital to explore the impact of hypertension and hypertension treatment on the severity and prognosis of patients with covid19, so as to provide new methods for the treatment of patients with covid19 in the future.

    NCT04318301
    Conditions
    1. COVID-19
    2. Hypertension
    MeSH:Hypertension
    HPO:Hypertension

    Primary Outcomes

    Description: mortality in 28-day

    Measure: Rate of Death

    Time: From date of admission until the date of death from any cause, up to 60 days

    Secondary Outcomes

    Description: evaluate the severity of pneumonia according to CT scans and clinical manifestation

    Measure: the severity of pneumonia

    Time: From date of admission until the date of discharge or death from any cause, up to 60 days

    Other Outcomes

    Description: days from admission to discharge or death

    Measure: the length of hospital stay

    Time: From date of admission until the date of discharge or death from any cause, up to 60 days
    4 The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial

    Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 is known to require the angiotensin-converting enzyme 2 (ACE-2) receptor for uptake into the human body, there have been questions about whether medications that upregulate ACE-2 receptors might increase the risk of infection and subsequent complications. One such group of medications are anti-hypertensives that block the renin-angiotensin system, including both angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB). Both ACEi and ARB are widely used for the treatment of hypertension. Early reports from China and Italy suggest that many of those who die from COVID-19 have a coexisting history of hypertension. Consequently, there have been questions raised as to whether these 2 types of blood pressure medication might increase the risk of death among patients with COVID-19. However, it is well known that the prevalence of hypertension increases linearly with age. Therefore, it is possible that the high prevalence of hypertension and ACEi/ARB use among persons who die from COVID-19 is simply confounded by age (older people are at risk of both a history of hypertension and dying from COVID-19). Whether these commonly prescribed blood pressure medications increase the risk of COVID-19 or not remains unanswered. Statements from professional cardiology societies on both sides of the Atlantic have called for urgent research into this question. Our study aims to randomize patients with primary (essential) hypertension who are already taking ACEi/ARB to either switch to an alternative BP medication or continue with the ACEi/ARB that they have already been prescribed. Adults with compelling indications for ACEi/ARB will not be enrolled.

    NCT04330300
    Conditions
    1. Hypertension
    2. COVID-19
    Interventions
    1. Drug: Thiazide or Thiazide-like diuretics
    2. Drug: Calcium Channel Blockers
    3. Drug: ACE inhibitor
    4. Drug: Angiotensin receptor blocker
    MeSH:Coronavirus Infections Hypertension
    HPO:Hypertension

    Primary Outcomes

    Description: Time from randomization to the first occurrence of any of the clinical events above

    Measure: Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)

    Time: 12 months

    Secondary Outcomes

    Description: Time from randomization to the first occurrence of above

    Measure: Number of Covid-19 positive participants who die

    Time: 12 months

    Description: Time from randomization to the first occurrence of above

    Measure: Number of Covid-19 positive participants who require intubation in intensive care unit (ICU)

    Time: 12 months

    Description: Time from randomization to the first occurrence of above

    Measure: Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV)

    Time: 12 months

    Description: Time from randomization to the first occurrence of above

    Measure: Number of SARS-CoV-2 positive participants

    Time: 12 months

    Measure: Maximum troponin T value (ng/L) among Covid-19 positive participants who require acute hospitalization

    Time: 12 months

    Description: Performed in a random sub-sample of the cohort (both study arms)

    Measure: 24 hour mean systolic BP (mmHg) on ambulatory BP monitoring

    Time: 12 months

    Description: Time from randomization to the first occurrence of above

    Measure: All-cause mortality

    Time: 12 months
    5 Phase IV Observational Study to Associate Hypertension and Hypertensinon Treatment to COVID19

    Multicentric non-profit observational study, in patients with COVID-19 hospitalized in Italy, conducted through a pseudonymised survey.

    NCT04331574
    Conditions
    1. COVID-19
    2. Hypertension
    3. Cardiovascular Diseases
    MeSH:Hypertension Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system Hypertension

    Primary Outcomes

    Description: Using anamnestic data collected from the health record of the hospital or of the general practitioner, we will count the number of COVID-19 patients enrolled that were treated with ACE Inhibitors or ARB.

    Measure: Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents

    Time: 3 months

    Description: This study want to observe whether the assumption of antihypertensive ACE inhibitors or ARB increases the severity of the clinical manifestation of COVID19

    Measure: Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents

    Time: 3 months

    Secondary Outcomes

    Description: Collecting selected data from the health record and hospital charts of the patients we will assess whether among the recorded parameters there are any that can predict COVID19 prevalence and severity

    Measure: Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity

    Time: 3 months
    6 ARB, ACEi, DRi Usage in COVID-19

    It is supposed to monitor hypertensive patients who are infected or have clinical manifestations of COVID-19 for 1 month after the onset of the disease. Three groups will be considered: 1. receiving ACE inhibitors 2. receiving ARBs 3. receiving DIR.

    NCT04364984
    Conditions
    1. Hypertension
    2. COVID-19
    Interventions
    1. Drug: Angiotensin converting enzyme inhibitor
    MeSH:Hypertension
    HPO:Hypertension

    Primary Outcomes

    Description: BP one week before COVID-19 infection and 3 weeks follow-up after COVID-19 onset

    Measure: BP (hypertensive efficacy)

    Time: through study completion, an average of 4 weeks

    Secondary Outcomes

    Description: number of patients with fever (above 37.2C)

    Measure: COVID-19 course

    Time: through study completion, an average of 3 weeks

    Description: number of patients with cough

    Measure: Cough in COVID-19 course

    Time: 12 weeks

    Description: number of patients with throat pain

    Measure: Throat pain in COVID-19 course

    Time: 2 weeks

    Description: number of patients with diarrhea

    Measure: Diarrhea inf COVID-19 course

    Time: 2 weeks

    Description: number of patients who need hospital and intensive care unit

    Measure: Need to apply to hospital in COVID-19 course

    Time: 24 weeks
    7 Prospective Monitoring of Drug Safety and the Occurrence of Complications During Hospitalization in Patients With Cardiovascular Diseases With COVID-19

    Hospitalized patients with COVID-19 will be included in the study in centers around Poland. After the hospitalization, a short questionnaire will be completed, including pre-hospitalization diagnoses, pre-hospitalization medications, clinical status on admission, the course, complication and the duration of hospitalization. The questionnaire will be available in paper form and on-line.

    NCT04374110
    Conditions
    1. COVID
    2. Hypertension
    3. Cardiovascular Diseases
    4. Cardiovascular Risk Factor
    Interventions
    1. Other: Clinical data
    MeSH:Hypertension Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system Hypertension

    Primary Outcomes

    Description: Death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke

    Measure: Adverse events

    Time: through study completion, an average of 2 weeks

    Secondary Outcomes

    Description: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints

    Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke

    Time: through study completion, an average of 2 weeks

    Description: Ventilation during hospitalization

    Measure: Ventilation during hospitalization

    Time: through study completion, an average of 2 weeks

    Description: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints

    Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke

    Time: prolonged follow up, through study completion, an average of one year
    8 Association Between Hypertension, Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19

    Background. Angiotensing converting enzyme type 2 (ACE2), a key enzyme of the renin-angiotensin-aldosterone system (RAAS), is the receptor of SARS-CoV-2 for cell entry into lungs. Because ACE2 may be modulated by RAAS inhibitors, such as angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs), there is concern that patients treated with ACEi and ARBs may be at higher risk for COVID-19 infection and severity. Aim. To analyze the associations between COVID-19 and hypertension, and treatments with ACEi and ARBs. Methods. In this retrospective observational study, consecutive patients hospitalized for suspected COVID-19 pneumonia will be divided into 2 groups, whether or not COVID-19 is confirmed. The two groups will be compared for baseline characteristics, mainly prior treatment with ACEi and ARBs, and clinical outcome at 1-month follow-up. The main hypothesis is that ACEi and ARBs, which interact differently with ACE2, may have different relationships with COVID-19 infection or severity.

    NCT04374695
    Conditions
    1. COVID-19
    MeSH:Hypertension
    HPO:Hypertension

    Primary Outcomes

    Description: Prevalence of a previous treatment by angiotensin converting enzyme inhibitors in patients with and without confirmed Covid-19 pneumonia.

    Measure: Prior treatment by ACEi

    Time: at admission to hospital

    Description: Prevalence of a previous treatment by angiotensin II type 1-receptor blockers in patients with and without confirmed Covid-19 pneumonia.

    Measure: Prior treatment by ARB

    Time: at admission to hospital

    Secondary Outcomes

    Description: Association between COVID-19 infection status and other baseline characteristics and comorbidities (age, sex, history of hypertension, chronic heart disease, diabetes mellitus, COPD, asthma, obesity, allergies)

    Measure: Baseline characteristics and comorbidities

    Time: at admission to hospital

    Description: Association between previous treatment by ACEi and ARBs and clinical course of COVID-19 (one-month mortality, hospitalization in intensive care unit, duration of hospital stay, early discharge to home)

    Measure: Major Clinical Adverse Events

    Time: One month follow-up
    9 COVID-19 Blood Pressure Endothelium Interaction Study

    The current COVID-19 pandemic (caused by the SARS-CoV-2 virus) represents the biggest medical challenge in decades. Whilst COVID-19 mainly affects the lungs it also affects multiple organ systems, including the cardiovascular system. There are documented associations between severity of disease and risk of death and To provide all the information required by review bodies and research information systems, we ask a number of specific questions. This section invites you to give an overview using language comprehensible to lay reviewers and members of the public. Please read the guidance notes for advice on this section. 5 DRAFT Full Set of Project Data IRAS Version 5.13 advancing age, male sex and associated comorbid disease (hypertension, ischaemic heart disease, diabetes, obesity, COPD and cancer). The most common complications include cardiac dysrhythmia, cardiac injury, myocarditis, heart failure, pulmonary embolism and disseminated intravascular coagulation. It is thought that the mechanism of action of the virus involves binding to a host transmembrane enzyme (angiotensin- converting enzyme 2 (ACE2)) to enter some lung, heart and immune cells and cause further damage. While ACE2 is essential for viral invasion, it is unclear if the use of the common antihypertensive drugs ACE inhibitors or angiotensin receptor blockers (ARBs) alter prognosis. This study aims to look closely at the health of the vascular system of patients after being treated in hospital for COVID-19 (confirmed by PCR test) and compare them to patients who had a hospital admission for suspected COVID-19 (negative PCR test) . Information from this study is essential so that clinicians treating patients with high blood pressure understand the impact of the condition and these hypertension medicines in the context of the current COVID-19 pandemic. This will allow doctors to effectively treat and offer advice to patients currently prescribed these medications or who are newly diagnosed with hypertension.

    NCT04409847
    Conditions
    1. COVID
    2. Hypertension
    Interventions
    1. Diagnostic Test: ABPM
    2. Diagnostic Test: ECG
    3. Diagnostic Test: FMD
    4. Diagnostic Test: PWV
    5. Diagnostic Test: Rarefaction
    MeSH:Hypertension
    HPO:Hypertension

    Primary Outcomes

    Description: Ambulatory Blood Pressure Monitoring systolic blood pressure

    Measure: ABPM systolic blood pressure

    Time: 24 hours (all day and night)

    Secondary Outcomes

    Description: Ambulatory Blood Pressure Monitoring diastolic blood pressure

    Measure: 24-hr ABPM DBP

    Time: 24 hours (all day and night)

    Description: Day Ambulatory Blood Pressure Monitoring systolic blood pressure

    Measure: day ABPM SBP

    Time: 8am to 8pm

    Description: Day Ambulatory Blood Pressure Monitoring diastolic blood pressure

    Measure: day ABPM DBP

    Time: 8am to 8pm

    Description: Night Ambulatory Blood Pressure Monitoring systolic blood pressure

    Measure: night ABPM SBP

    Time: 8pm to 8am

    Description: Night Ambulatory Blood Pressure Monitoring diastolic blood pressure

    Measure: night ABPM DBP

    Time: 8pm to 8am

    Description: The fall in pressure, called the "dip", is defined as the difference between daytime mean systolic pressure and nighttime mean systolic pressure expressed as a percentage of the day value

    Measure: dipping status

    Time: 24 hours (all day and night)

    Description: he morning surge was defined as the difference between the mean systolic blood pressure during the 2 hours after waking and arising minus the mean systolic blood pressure during the hour that included the lowest blood pressure during sleep.

    Measure: morning surge

    Time: 24 hours (all day and night)

    Description: 24 hour Ambulatory Blood Pressure Monitoring heart rate

    Measure: 24 hour ABPM HR

    Time: 24hr (all day and night)

    Description: Day Ambulatory Blood Pressure Monitoring heart rate

    Measure: day ABPM HR

    Time: 8 am to 8 pm

    Description: Night Ambulatory Blood Pressure Monitoring heart rate

    Measure: night ABPM HR

    Time: 8pm to 8 am
    10 The Prevalence of Pulmonary Hypertension, With or Without Right Ventricular Loading, in Patients With COVID-19 Who Are Being Treated With a Respirator in the Intensive Care Unit.

    The virus infection Covid-19 fills our hospitals and intensive care departments in a very unique way and there is a lack of essential insight into the pathophysiology of the disease. As a result, very specific treatment options are missing. The US Medicines Agency (FDA) has in the last days given a general license for treatment with inhaled nitric oxide (iNO). Inhaled NO in Sweden (and Europe) is approved for the indication of pulmonary hypertension in adults. However, no one has yet described the occurrence of pulmonary hypertension, with or without right ventricular loading, in the Covid-19 patients who become so seriously ill that they need to be treated at an IVA ward. Knowledge of this is, of course, a prerequisite for determining the need for pulmonary artery catheterization (PA catheter, Swan-Ganz catheter) and also to better understand whether iNO treatment or other forms of lung selective vasodilation therapy may be of benefit to this patient group.

    NCT04459364
    Conditions
    1. Hypertension, Pulmonary
    2. Right Ventricular Overload
    3. COVID
    MeSH:Hypertension, Pulmonary Hypertension
    HPO:Hypertension Pulmonary arterial hypertension

    Primary Outcomes

    Description: To determine the prevalence of pulmonary hypertension and right ventricular load in patients with COVID-19 treated in intensive care unit evaluated by routine echocardiography.

    Measure: Prevalence

    Time: Day 1
    11 Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, enters type II pneumocytes using angiotensin-converting enzyme 2 (ACE2). It is unclear whether ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) increase, decrease, or have no significant effect on ACE2 expression or activity. Therefore, ACEI and ARB may be harmful, beneficial, or have no impact on Coronavirus Disease 2019 severity and mortality. The Specific Aims of this observational study are: (1) Among SARS-CoV-2-positive outpatients, compare all-cause hospitalization and mortality rates between: 1.1 Current users of a range of doses of ACEI/ARB- vs. non- ACEI/ARB-based regimens, and 1.2 Current users of a range of doses of ACEI- vs. ARB-based regimens, and (2) Among those hospitalized for COVID-19, compare all-cause mortality between: 2.1 Current users of a range of doses of ACEI/ARB- vs. non- ACEI/ARB-based regimens, and 2.2 Current users of a range of doses of ACEI- vs. ARB-based regimens.

    NCT04467931
    Conditions
    1. Hypertension
    2. COVID
    Interventions
    1. Drug: ACEI/ARB
    2. Drug: Non-ACEI/ARB
    3. Drug: ACEI
    4. Drug: ARB
    MeSH:Hypertension
    HPO:Hypertension

    Primary Outcomes

    Description: For outpatient Veterans with a positive SARS-CoV-2 test (Aims 1.1 and 1.2), the primary outcome is a composite of time to all-cause hospitalization or all-cause mortality.

    Measure: All-Cause-Hospitalization or All-Cause Mortality

    Time: Through study completion (approximately July 31, 2020).

    Description: For Veterans hospitalized with COVID-19 (Aims 2.1 and 2.2), the primary outcome is time to all-cause mortality.

    Measure: All-Cause Mortality

    Time: Through study completion (approximately July 31, 2020).

    Secondary Outcomes

    Description: For aims 1 and 2, a secondary outcome will be time to intensive care unit (ICU) admission.

    Measure: ICU admission

    Time: Through study completion (approximately July 31, 2020).

    Description: For aims 1 and 2, a secondary outcome will be duration of hospitalization.

    Measure: Duration of hospitalization

    Time: Through study completion (approximately July 31, 2020).

    Description: For aim 2, a secondary outcome will be time to mechanical ventilation.

    Measure: Mechanical ventilation

    Time: Through study completion (approximately July 31, 2020).

    Description: For aim 2, a secondary outcome will be time to in-hospital dialysis.

    Measure: Dialysis

    Time: Through study completion (approximately July 31, 2020).

    Other Outcomes

    Description: Time to gastrointestinal bleed. This will be a negative control outcome.

    Measure: Gastrointestinal bleed

    Time: Through study completion (approximately July 31, 2020).

    Description: Time to urinary tract infection. This will be a negative control outcome.

    Measure: Urinary tract infection

    Time: Through study completion (approximately July 31, 2020).
    12 Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness

    With the appearance of the new SARS-COV2 virus, additional challenges are being imposed on the medical community after the resolution of acute COVID-19 illness, resulting in specific pathophysiologic mechanisms that while acutely damage the lung parenchyma might chronically impact the cardiopulmonary system. This study aims to investigate changes after mild COVID-19 illness in echocardiographic indices at rest and stress.

    NCT04498299
    Conditions
    1. Echocardiography, Stress
    2. COVID-19
    3. Hypertension, Pulmonary
    Interventions
    1. Diagnostic Test: echocardiogram 2D
    MeSH:Hypertension, Pulmonary Hypertension
    HPO:Hypertension Pulmonary arterial hypertension

    Primary Outcomes

    Description: Left atrium volume index

    Measure: • LA volume index

    Time: 3 minutes

    Description: Left ventricle telediastolic diameter

    Measure: • LV telediastolic diameter

    Time: 3 minutes

    Description: Left ventricle telesystolic diameter

    Measure: • LV telesystolic diameter

    Time: 3 minutes

    Description: Left ventricle posterior wall

    Measure: • LV posterior wall

    Time: 3 minutes

    Description: Right atrium area

    Measure: • RA area

    Time: 3 minutes

    Description: Right ventricle basal dimensión

    Measure: • RV basal dimensión

    Time: 3 minutes

    Description: Right ventricle cavity dimensión

    Measure: • RV mid cavity dimension;

    Time: 3 minutes

    Description: Right ventricle longitudinal dimension

    Measure: • RV longitudinal dimension

    Time: 3 minutes

    Description: Distal, right ventricle outflow tract dimension at the distal or pulmonic valve level

    Measure: • Distal, RV outflow tract dimension at the distal or pulmonic valve level

    Time: 3 minutes

    Description: Proximal right ventricle outflow tract dimension at the proximal subvalvular level

    Measure: • Proximal RV outflow tract dimension at the proximal subvalvular level

    Time: 3 minutes

    Description: • Tricuspid annular plane systolic excursion

    Measure: • TAPSE

    Time: 3 minutes

    Description: Right ventricle free Wall strain

    Measure: • RV free Wall strain

    Time: 3 minutes

    Description: Inferior cava vein PW Doppler

    Measure: • Inferior cava vein PW Doppler

    Time: 3 minutes

    Description: E wave mitral

    Measure: • E wave mitral

    Time: 3 minutes

    Description: A wave mitral

    Measure: • A wave mitral

    Time: 3 minutes

    Description: E wave /A wave mitral

    Measure: • E wave /A wave mitral

    Time: 3 minutes

    Description: E-wave at mitral annulus

    Measure: • E-wave at mitral annulus

    Time: 3 minutes

    Description: E-wave at mitral annulus / A-wave at the mitral annulus

    Measure: • E-wave at mitral annulus / A-wave at the mitral annulus

    Time: 3 minutes

    Description: E wave/ E-wave at the mitral annulus

    Measure: • E wave/ E-wave at the mitral annulus

    Time: 3 minutes

    Description: E tricuspid (E)

    Measure: • E tricuspid (E)

    Time: 3 minutes

    Description: A triuspid (A)

    Measure: • A tricuspid (A)

    Time: 3 minutes

    Description: E/A

    Measure: • E/A

    Time: 3 minutes

    Description: Systolic pulmonary artery pressure

    Measure: • Systolic pulmonary artery pressure

    Time: 3 minutes

    Description: E-wave at the tricuspid annulus

    Measure: • E-wave at the tricuspid annulus

    Time: 3 minutes

    Description: Mean pulmonary artery pressure

    Measure: • Mean pulmonary artery pressure

    Time: 3 minutes

    Description: Stroke volume

    Measure: • Stroke volume

    Time: 3 minutes

    Description: Cardiac output

    Measure: • Cardiac output

    Time: 3 minutes
    13 Effect of a Nutritional Support System to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III

    The disease caused by SARS-CoV-2, has derived a pandemic in which its evolution and complications depend on the immune capacity of the host. The virus has been characterized by presenting an inflammatory cascade, increased by the overproduction of proinflammatory cytokines, the decrease in metalloenzymes and also the rapid spread of the virus. There are several lines of treatment, however, nutritional treatment only considered a caloric intake. For this reason, this study will evaluate the evolution of patients with COVID-19 assisted by nutritional support based on supplements such as omega 3, zinc, selenium, vitamin D, glutamine, prebiotics, and foods such as spirulina and the effect of this therapy in reducing complications and comorbidities. Research question: Will the nutritional support system reduce complications in stage III positive COVID-19 patients with comorbidities (type 2 DM, SAH, overweight / obesity with BMI <35), with a better benefit than that achieved with the conventional nutritional treatment ?. Hypothesis: The nutritional support system will reduce the complications of patients with COVID-19 in stage III with comorbidities. General Objective: To determine the effect of the use of a nutritional support system on complications in patients with COVID-19 in stage III with comorbidities. Methodology: A controlled, blinded, randomized clinical trial will be conducted in patients with COVID-19, hospitalized at the ISSEMYM Toluca Arturo Montiel Rojas Medical Center, who meet the inclusion criteria. The evolution of the group of patients receiving the nutritional support system (NSS) and the normal diet implemented by the hospital will be evaluated against the group of patients receiving only the diet, using laboratory and cabinet tests during their hospital stay. Statistical analysis: for independent groups with normal distribution, Student's T will be applied. If the distribution does not meet normality criteria, a Mann Whitney U will be performed; Two-way ANOVA will be applied to monitor the groups over time with normal distribution. If the distribution does not meet normality criteria, a Friedman test will be performed, in both cases post hoc tests will be performed. The results will be analyzed using version 8 of the Graphpad Prism software.

    NCT04507867
    Conditions
    1. Covid19
    2. Diabetes Mellitus
    3. Hypertension
    4. Obesity
    Interventions
    1. Dietary Supplement: Nutritional support system (NSS)
    2. Other: Control
    MeSH:Hypertension
    HPO:Hypertension

    Primary Outcomes

    Description: Fraction of oxygen-saturated hemoglobin relative to the patient's total blood hemoglobin, represented as a percentage. Measurement using the pulse oximeter of the multi-parameter vital signs monitor. Measurement units % SpO2.

    Measure: Oxygen saturation

    Time: 1 minute

    Description: Balance between the production of heat by the body and its loss. Measurement using an infrared thermometer. Units of measure degrees centigrade.

    Measure: Body temperature

    Time: 30 seconds

    Description: Force exerted by the blood against the walls of the vessels (arteries) as it is pumped by the heart. Measurement using the multi-parameter vital signs monitor. Units of measurement in mmHg. Obtain systolic and diastolic pressure.

    Measure: Blood pressure

    Time: 2 minutes

    Description: Number of times the heart beats for a certain period of time, measured by the multi-parameter vital signs monitor. Units of measure beats per minute.

    Measure: Heart rate

    Time: 1 minute

    Description: Number of breaths that a living being takes during a certain period of time, Count daily with the patient at rest the number of breaths for one minute each time the chest rises. Measured in breaths per minute.

    Measure: Breathing frequency

    Time: 1 minute

    Description: Disruption of the organic functions of any living being. The existence of the death certificate will be reviewed daily. Categories: dead or alive.

    Measure: Death

    Time: 10 seconds

    Description: Simultaneous knowledge, in the unity of time, of oneself (subject) and of the surrounding world (object), is the reflection of reality. It will be evaluated daily with the glasgow scale. Categories: 1.13-15 points. 2. 9-12 points. 3. 3-8 points.

    Measure: Awareness

    Time: 2 minutes

    Description: Number of days that the patient remains hospitalized. It is reviewed daily if the patient has been discharged. Categories: 1.Hopitalized. 2. Released.

    Measure: Hospital stay

    Time: 10 seconds

    Description: Rapid sequential evaluation of organic failures. Evaluate daily the qSOFA items and get your score. Measure in points.

    Measure: qSOFA score

    Time: 1 minute

    Description: Clinically and study-based acquired need to open the airway in order to supply him with oxygen. Check daily if a cannula or tube was placed in the windpipe. Categories: 1.Progress to ventilation. 2. Does not progress to ventilation.

    Measure: Progression to ventilation

    Time: 10 seconds

    Description: Need for a multidisciplinary team, for presenting an acute critical state, with the support of technological resources for monitoring, diagnosis and treatment. It is reviewed daily if the patient is directed to ICU. Categories: 1.Enter ICU. 2. You do not enter ICU.

    Measure: Progression to Intensive Care Unit

    Time: 10 seconds

    Description: Any localized painful discomfort in the head. Evaluate and ask for pain by numbering it from 1-10, where 0 is the absence and 10 is the greatest intensity (Daily, 2 shifts, 21 days).

    Measure: Cephalea

    Time: 10 seconds

    Description: Physical actions that you can take without pain or discomfort. Evaluate what movements and activities he tolerates (Daily, 2 shifts, 21 days). Categories: 1.Walk. 2.He can stand 3.Sit. 4.Postrate.

    Measure: Activity level

    Time: 10 seconds

    Description: Body postures that are used to facilitate the examination of the patient, his treatment, the prevention of injuries due to immobility, and his comfort when he is bedridden. Observe the anatomical position in which he is found (Daily, 2 shifts, 21 days). Categories: 1. In the prone position. 2.In the supine position. 3.Fowler. 4.Semifowler. 5.Other

    Measure: Anatomic position

    Time: 10 seconds

    Description: Evaluate the level of hydration of the hair (Daily, morning, 21 days). Categories: 1.Hydrated, shiny. 2.Opaque. 3.Very dull and dry.

    Measure: Hair hydration

    Time: 19 seconds

    Description: Evaluate hair loss with the "pull sign" by pulling the hair without the intention of plucking, daily in the morning (Daily, morning, 21 days).Categories 1. <5 hairs on hand. 2. 5-10 hairs. 3.> 10 hairs.

    Measure: Hair loss

    Time: 20 seconds

    Description: Targeted search for one or more asymptomatic sudden onset decalvary patches throughout the hair territory (Daily, morning, 21 days). Categories: 1. Without decalvary plates. 2. With regional decalvary plates. 3. Generalized alopecia areata.

    Measure: Decalvary patches

    Time: 10 seconds

    Description: Inspect the scalp for lesions (Daily, morning, 21 days). Categories: 1.No injuries. 2. Flaking. 3.Erythema. 4.Infection. 5. Bleeding.

    Measure: Scalp lesions

    Time: 15 seconds

    Description: Ask about itching of the scalp (Daily, morning, 21 days). Categories: 1.Without itching. 2.Itching.

    Measure: Itching scalp

    Time: 10 seconds

    Description: Evaluate the absence or loss of eyelashes, daily in the morning. Categories: 1.Without alterations. 2.White spaces. 3. Fall when exploring.

    Measure: Loss of eyelashes

    Time: 15 seconds

    Description: Evaluate the absence or drooping of eyebrows (Daily, morning, 21 days). Categories: 1. Without alterations. 2.White spaces. 3. Fall when exploring.

    Measure: Drooping of eyebrows

    Time: 10 seconds

    Description: Evaluate eyelid edema (Daily, morning, 21 days). Categories: 1. Without edema. 2. With edema

    Measure: Eyelid edema

    Time: 5 seconds

    Description: Check the vascularity of the sclera (Daily, morning, 21 days). Categories: 1.White sclera. 2.Small blood vessels. 3. Large blood vessels. 4.Hemorrhage.

    Measure: Vascularity of the sclera

    Time: 10 seconds

    Description: Assess ocular hydration (Daily, morning, 21 days). Categories: 1.Hydrated. 2.Dry mucus. 3.Absence of tears. 4 sunken eyes

    Measure: Ocular hydration

    Time: 15 seconds

    Description: Evaluate sclera color, daily in the morning. Categories: 1.White. 2. Localized yellow. 3.General yellow. 4.Other colors.

    Measure: Sclera color

    Time: 10 seconds

    Description: Evaluation of smell, presenting non-irritating odors and ask if it distinguishes them (Daily, morning, 21 days). Categories: 1.Normal. 2. Hyposmia. 3.Anosmia.

    Measure: Sense of smell

    Time: 30 seconds

    Description: Evaluate the presence of irritation in the nostrils (Daily, morning, 21 days). Categories: 1.No irritation. 2.With irritation.

    Measure: Irritation in the nostrils

    Time: 10 seconds

    Description: Assess nasal secretions (Daily, morning, 21 days). Categories: 1. Absence. 2.Transparent. 3.Of other colors. 4.With blood.

    Measure: Nasal secretions

    Time: 10 seconds

    Description: Evaluate the presence of cheilitis (Daily, morning, 21 days). Categories: 1.Without cheilitis. 2.Unilateral. 3.Bilateral. 4.With ulcers.

    Measure: Cheilitis

    Time: 5 seconds

    Description: Assess taste buds (Daily, morning, 21 days). Categories: 1. Normal. 2. Inflamed. 3. Painful. 4. Bleeding.

    Measure: Taste buds

    Time: 10 seconds

    Description: Evaluate the presence of the saw edge of the tongue (Daily, morning, 21 days). Categories 1.Normal. 2.Flat 3.With serrated edge.

    Measure: Saw edge of the tongue

    Time: 10 seconds

    Description: Look for changes in the body of the tongue (Daily, morning, 21 days). Categories: 1.No alterations. 2.Geographic. 3.Fissured.

    Measure: Changes in the body of the tongue

    Time: 10 seconds

    Description: Look for changes in the thickness of the tongue (Daily, morning, 21 days). Categories: 1. Normal thickness. 2. Abnormal thickness, swollen.

    Measure: Thickness of the tongue

    Time: 5 seconds

    Description: Assess the presence of salivation (Daily, morning, 21 days). Categories: 1.Normal. 2.Excessive salivation. 3 absent.

    Measure: Salivation

    Time: 10 seconds

    Description: Evaluate the taste presenting food from their tray and ask if you distinguish the flavors (Daily, morning, 21 days). Categories: 1.Conserved. 2. Hypogeusia. 3.Ageusia.

    Measure: Taste

    Time: 30 seconds

    Description: Evaluation of the gums (Daily, morning, 21 days). Categories: 1.Normal. 2.Hypersensitive 3.Inflamed. 4. Bleeding.

    Measure: Gums

    Time: 10 seconds

    Description: Evaluation of skin sensitivity (Daily, morning, 21 days). Categories: 1.Normal. 3.Altered sensitivity. 3.Painful.

    Measure: Skin sensitivity

    Time: 30 seconds

    Description: Assess the presence of lesions (Daily, morning, 21 days). Categories: 1. No lesions. 2.Dermatitis. 3. Open lesions.

    Measure: Skin lesions

    Time: 10 seconds

    Description: Assess skin hydration (Daily, morning, 21 days). Categories: 1.Normal. 2.Fat. 3.Dry.

    Measure: Skin hydration

    Time: 10 seconds

    Description: Evaluate skin texture (Daily, morning, 21 days). Categories: 1.Lisa. 2.Rugose. 3.Descamative

    Measure: Skin texture

    Time: 10 seconds

    Description: Check for loss or absence of body hair (Daily, morning, 21 days). Categories: 1.Present. 2.Fall. 3.Absence.

    Measure: Absence of body hair

    Time: 10 seconds

    Description: Evaluate by finger pressure the 7th cervical hypersensitivity (Every 2 days, morning, 21 days). Categories: 1. It does not cause pain. 2. It causes pain.

    Measure: Cervical pain points

    Time: 5 seconds

    Description: Search for hypersensitivity on the inside of the forearm (Every 2 days, morning, 21 days)

    Measure: Forearm pain points

    Time: 5 seconds

    Description: Ask if he presents odynophagia (Daily, 2 shifts, 21 days). Categories: 1.Absent. 2. Present.

    Measure: Odynophagia

    Time: 5 seconds

    Description: Evaluation of the presence of cough (Daily, 2 shifts, 21 days). Categories: 1.Absent. 2.Productive. 3.Dry

    Measure: Cough

    Time: 5 seconds.

    Description: Evaluation of the presence of sneezing (Daily, 2 shifts, 21 days). Categories: 1. Absent. 2. Present.

    Measure: Sneezing

    Time: 5 seconds

    Description: Respiration rhythm evaluation (Daily, 2 shifts, 21 days). Categories: 1. Normal. 2.Altered.

    Measure: Respiration rhythm

    Time: 1 minute

    Description: Assessment of abdominal breathing (Daily, 2 shifts, 21 days). Categories: 1.Absent. 2. Present.

    Measure: Abdominal breathing

    Time: 20 seconds

    Description: Evaluation of the use of accessory muscles when breathing (Daily, 2 shifts, 21 days). Categories: 1.Absent. 2. Present.

    Measure: Use of accessory muscles when breathing

    Time: 10 seconds

    Description: Evaluate the presence of xiphoid retraction when breathing (Daily, 2 shifts, 21 days). Categories: 1. Absent. 2. Present.

    Measure: Xiphoid retraction when breathing

    Time: 10 seconds

    Description: Assess the presence and degree of dyspnea (Daily, 2 shifts, 21 days). Categories: 1.Without difficulty. 2.When standing. 3.When sitting. 2.When speaking, 3.Lying down.

    Measure: Dyspnea

    Time: 10 seconds

    Description: Evaluate the abdomino-cutaneous reflexes (Diary, verpertino, 21 days). Categories: 1. Present. 2. Absent

    Measure: Abdomino-cutaneous reflexes

    Time: 20 seconds

    Description: Assess rebound sensitivity (Daily, verpertino, 21 days). Categories: 1. Without sensitivity. 2. With sensitivity.

    Measure: Rebound sensitivity

    Time: 15 seconds

    Description: Evaluate the presence of pain in the right hypochondrium. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

    Measure: Right hypochondrium

    Time: 5 seconds

    Description: Evaluate the presence of pain in the epigastrium. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

    Measure: Epigastrium

    Time: 5 seconds

    Description: Evaluate the presence of pain in the left hypochondrium. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

    Measure: Left hypochondrium

    Time: 5 seconds

    Description: Assess the presence of pain in the right flank. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

    Measure: Right flank

    Time: 5 seconds

    Description: Assess the presence of pain in the mesogastrium (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

    Measure: Mesogastrium

    Time: 5 seconds

    Description: Evaluate the presence of pain in the left flank. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

    Measure: Left flank

    Time: 5 seconds

    Description: Evaluate the presence of pain in the right iliac fossa. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

    Measure: Right iliac fossa.

    Time: 5 seconds

    Description: Evaluate the presence of pain in the hypogastrium. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

    Measure: Hypogastrium

    Time: 5 seconds

    Description: Assess the presence of pain in the left iliac fossa. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

    Measure: Left iliac fossa.

    Time: 5 seconds

    Description: Ask for the presence of vomiting in 24 hours (Daily, evening, 21 days). Categories: 1. Absent. 2. Present.

    Measure: Vomiting

    Time: 5 seconds

    Description: Ask about the presence of appetite (Daily, evening, 21 days). Categories: 1. Increased appetite. 2.Normal 3.Hypoexia. 4.Anorexia.

    Measure: Appetite

    Time: 5 seconds

    Description: Ask about the presence of reflux (Daily, evening 21 days). Categories: 1. Absent. 2. After eating (specify food). 3. At bedtime. 4. Sudden

    Measure: Reflux

    Time: 5 seconds

    Description: Ask about the presence of more common burps than normal (Daily, evening, 21 days). Categories: 1.Normales 2. Augmented.

    Measure: Burps

    Time: 5 seconds

    Description: Evaluation of defecation by means of bowel movements with the Bristol scale (Daily, evening, 21 days). Categories: 1.Normal (T3, T4) 2.Constipation (T1, T2). 3. Diarrhea (T5, T6, T7).

    Measure: Bristol scale

    Time: 10 seconds

    Description: Evaluation of hair loss on legs (Every 2 days, evening, 21 days) Categories: 1. Without alterations. 2.White spaces. 3. Fall when exploring.

    Measure: Hair loss on legs

    Time: 10 seconds

    Description: Evaluation of the sensitivity of the tibial tract (Every 2 days, evening, 21 days) Categories: 1. No pain. 2.Painful.

    Measure: Sensitivity of the tibial tract

    Time: 10 seconds

    Description: Assessment of nail strength (Every 2 days, evening, 21 days). Categories: 1. Strong. 2. Brittle. 3.Not assessable.

    Measure: Nail strength

    Time: 10 seconds

    Description: Check the presence of fungus in the nails of the hands (Every 2 days, evening, 21 days). Categories: 1. Absent. 2. Present. 3.Not assessable.

    Measure: Fungus in the nails of the hands

    Time: 10 seconds

    Description: Look for the presence of white stripes on the nails (Every 2 days, evening, 21 days). Categories: 1. Absent. 2. Present. 3.Not assessable.

    Measure: White stripes on the nails

    Time: 5 seconds

    Description: Look for the presence of white spots on the nails (Every 2 days, evening, 21 days). Categories: 1. Absent. 2. Present. 3.Not assessable.

    Measure: White spots on the nails

    Time: 5 seconds

    Description: Look for the presence of ridges on the nails (Every 2 days, evening, 21 days). Categories: 1.Lisas. 2.With ridges. 3.Not assessable.

    Measure: Ridges on the nails

    Time: 5 seconds

    Description: Taking the height (at the beginning of the protocol). Measure in cm.

    Measure: Height

    Time: 1 minute

    Description: Weight taking (Every 2 days, 2 hours after breakfast, for 21 days). Measured in kg.

    Measure: Weight

    Time: 1 minute

    Description: Calculation of BMI (Every 2 days, morning, for 21 days). Measured in kg / m2.

    Measure: BMI

    Time: 30 seconds

    Description: Measurement by blood sample of erythrocytes (Every 3 days, for 21 days). Measured at 10 ^ 6 / uL.

    Measure: Erythrocytes

    Time: 20 seconds

    Description: Measurement by blood sample of hemoglobin (Every 3 days, for 21 days). Measured in g / dL.

    Measure: Hemoglobin

    Time: 20 seconds

    Description: Measurement by blood sample of hematocrit (Every 3 days, for 21 days). Measurement in %.

    Measure: Hematocrit

    Time: 20 seconds

    Description: Measurement by blood sample of mean corpuscular volume (MCV) (Every 3 days, for 21 days). Measured in fL.

    Measure: Mean corpuscular volume

    Time: 20 seconds

    Description: Measurement by blood sample of mean hemoglobin concentration (Every 3 days, for 21 days). Measurement in pg.

    Measure: Mean hemoglobin concentration

    Time: 20 seconds

    Description: Measurement every 3 days by blood sample of mean corpuscular hemoglobin concentration (Every 3 days, for 21 days). Measured in g / dL

    Measure: Mean corpuscular hemoglobin concentration

    Time: 20 seconds

    Description: Erythrocyte distribution width measurement by blood sample (Every 3 days, for 21 days). Measured in%.

    Measure: Erythrocyte distribution width

    Time: 20 seconds

    Description: Measurement by blood sample of the hemoglobin distribution index (Every 3 days, for 21 days). Measured in g / dL.

    Measure: Hemoglobin distribution index

    Time: 20 seconds

    Description: Measurement by blood sample of leukocytes (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

    Measure: Leukocytes

    Time: 20 seconds

    Description: Measurement by blood sample of neutrophils (%) (Every 3 days, for 21 days). Measurement in%

    Measure: Neutrophils (%)

    Time: 20 seconds

    Description: Measurement by blood sample of neutrophils (#) (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

    Measure: Neutrophils (#)

    Time: 20 seconds

    Description: Measurement by blood sample of lymphocytes (%) (Every 3 days, for 21 days). Measurement in%

    Measure: Lymphocytes (%)

    Time: 20 seconds

    Description: Measurement by blood sample of lymphocytes (#) (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

    Measure: Lymphocytes (#)

    Time: 20 seconds

    Description: Measurement by blood sample of monocytes (%) (Every 3 days, for 21 days). Measurement in%

    Measure: Monocytes (%)

    Time: 20 seconds

    Description: Measurement by blood sample of monocytes (#) (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

    Measure: Monocytes (#)

    Time: 20 seconds

    Description: Measurement by blood sample of eosinophils (%) (Every 3 days, for 21 days). Measurement in%

    Measure: Eosinophils (%)

    Time: 20 seconds

    Description: Measurement by blood sample of eosinophils (#) (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

    Measure: Eosinophils (#)

    Time: 20 seconds

    Description: Measurement by blood sample of basophils (%) (Every 3 days, for 21 days). Measurement in%

    Measure: Basophils (%)

    Time: 20 seconds

    Description: Measurement by blood sample of basophils (#) (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

    Measure: Basophils (#)

    Time: 20 seconds

    Description: Measurement of prothrombin time (PT) by blood sample (Every 3 days, for 21 days). Measure in seconds

    Measure: Prothrombin time

    Time: 20 seconds

    Description: Measurement by blood sample of INR (Every 3 days, for 21 days). Measure in units

    Measure: INR

    Time: 20 seconds

    Description: Measurement by control blood sample (100-50) (Every 3 days, for 21 days). Measure in seconds

    Measure: Control blood sample (100-50) 1

    Time: 20 seconds

    Description: Measurement by blood sample of partial thromboplastin time (Every 3 days, for 21 days). Measure in seconds

    Measure: Partial thromboplastin time

    Time: 20 seconds

    Description: Measurement by control blood sample (100-50) (Every 3 days, for 21 days). Measure in seconds

    Measure: Control blood sample (100-50) 2

    Time: 20 seconds

    Description: Measurement by blood sample of platelets. Measured in 10 ^ 3 / μL

    Measure: Platelets

    Time: 20 seconds

    Description: Measurement by blood sample of mean platelet volume (MPV) (Every 3 days, for 21 days). Measured in fL.

    Measure: Mean platelet volume

    Time: 20 seconds

    Description: Initial screening test to diagnose patients with signs or symptoms suggestive of venous thromboembolism, it is a marker of endogenous fibrinolysis. Measurement by blood sample of dimer D (Every 3 days, for 21 days). Measured in ng / mL

    Measure: D-dimer

    Time: 20 seconds

    Description: Sulfur amino acid that originates in the metabolism of methionine, and is very aggressive for the arterial endothelium. Measurement by blood sample of homocysteine levels (Every 3 days, for 21 days). Measured in µmol / l.

    Measure: Homocysteine

    Time: 20 seconds

    Description: Fat-soluble vitamin involved in calcium homeostasis and bone metabolism, regulation of genes involved in the regulation of cell proliferation, cell differentiation and apoptosis. It has been suggested that it exerts immunomodulatory and antiproliferative effects. Measurement by blood sample of levels of 25-hydroxycholecalciferol (Every 3 days, for 21 days). Measured in nmol / L

    Measure: Vitamin D

    Time: 20 seconds

    Description: Measurement by blood sample of calcium (Every 3 days, for 21 days). Measured in mg / dL.

    Measure: Calcium

    Time: 20 seconds

    Description: Measurement by blood sample of phosphorus (Every 3 days, for 21 days). Measured in mg / dL.

    Measure: Phosphorus

    Time: 20 seconds

    Description: Measurement by blood sample of magnesium (Every 3 days, for 21 days). Measured in mg / dL.

    Measure: Magnesium

    Time: 20 seconds

    Description: Measurement by blood sample of sodium (Every 3 days, for 21 days). Measured in mmol / L.

    Measure: Sodium

    Time: 20 seconds

    Description: Measurement by blood sample of potassium (Every 3 days, for 21 days). Measured in mmol / L.

    Measure: Potassium

    Time: 20 seconds

    Description: Measurement by blood sample of chlorine (Every 3 days, for 21 days). Measured in mmol / L.

    Measure: Chlorine

    Time: 20 seconds

    Description: A measure of the concentration of free glucose in the blood, serum or blood plasma. Measured in mg / dL.

    Measure: Blood glucose

    Time: 20 seconds

    Description: Taking a blood sample of total cholesterol (Every 3 days, for 21 days). Measured in mg / dL.

    Measure: Total cholesterol

    Time: 20 seconds

    Description: Taking a blood sample of triglycerides (Every 3 days, for 21 days). Measured in mg / dL.

    Measure: Triglycerides

    Time: 20 seconds

    Description: Taking a blood sample of LDL cholesterol (Every 3 days, for 21 days). Measured in mg / dL.

    Measure: LDL cholesterol

    Time: 20 seconds

    Description: Taking a blood sample for HDL cholesterol (Every 3 days, for 21 days). Measured in mg / dL.

    Measure: HDL cholesterol

    Time: 20 seconds

    Description: Taking a blood sample to evaluate the level of aspartate aminotransferase (Every 3 days, for 21 days). Measured in U / L.

    Measure: Aspartate aminotransferase

    Time: 20 seconds

    Description: Taking a blood sample to evaluate the level of alanine aminotransferase (Every 3 days, for 21 days). Measured in U / L.

    Measure: Alanine aminotransferase

    Time: 20 seconds

    Description: Taking a blood sample to evaluate the total bilirubin level (Every 3 days, for 21 days). Measured in mg / dL.

    Measure: Total bilirubin

    Time: 20 seconds

    Description: Taking a blood sample to evaluate the level of direct bilirubin (Every 3 days, for 21 days). Measured in mg / dL.

    Measure: Direct bilirubin

    Time: 20 seconds

    Description: Taking a blood sample to evaluate the level of indirect bilirubin (Every 3 days, for 21 days). Measured in mg / dL.

    Measure: Indirect bilirubin

    Time: 20 seconds

    Description: Taking a blood sample to evaluate the level of alkaline phosphatase (Every 3 days, for 21 days). Measured in U / L.

    Measure: Alkaline phosphatase

    Time: 20 seconds

    Description: Taking a blood sample to evaluate the level of total proteins (Every 3 days, for 21 days). Measured in g / dL.

    Measure: Total proteins

    Time: 20 seconds

    Description: Taking a blood sample to evaluate the albumin level (Every 3 days, for 21 days). Measured in g / dL.

    Measure: Albumin level

    Time: 20 seconds

    Description: Taking a blood sample to evaluate the globulin level (Every 3 days, for 21 days). Measured in g / dL.

    Measure: Globulin level

    Time: 20 seconds

    Description: Taking a blood sample to evaluate the A / G ratio (Every 3 days, for 21 days). Measured in g / dL.

    Measure: A / G ratio

    Time: 20 seconds

    Description: ake a blood sample to evaluate the levels of urea nitrogen (Every 3 days, for 21 days). Measured in mg / dL.

    Measure: Urea nitrogen

    Time: 20 seconds

    Description: Take a blood sample to evaluate urea levels (Every 3 days, for 21 days). Measured in mg / dL.

    Measure: Urea

    Time: 20 seconds

    Description: Take a blood sample to evaluate creatitine levels (Every 3 days, for 21 days). Measured in mg / dL.

    Measure: Creatitine

    Time: 20 seconds

    Description: Take a blood sample to evaluate uric acid levels (Every 3 days, for 21 days). Measured in mg / dL.

    Measure: Uric acid

    Time: 20 seconds

    Description: Take a blood sample to evaluate ferritin levels (Every 3 days, for 21 days). Measured in ng/mL.

    Measure: Ferritin

    Time: 20 seconds

    Description: Take a blood sample to evaluate fibrinogen levels (Every 3 days, for 21 days). Measured in mg / dL.

    Measure: Fibrinogen

    Time: 20 seconds

    Description: Take a blood sample to evaluate the levels of C-reactive protein (Every 3 days, for 21 days). Measured in mg/L.

    Measure: C-reactive protein

    Time: 20 seconds

    Description: Use of the appropriate procedures established in the NSS indications (Specific supplementation scheme, based on 1 sachet, intramuscular B vitamins and probiotics). Quantification of empty supplement envelopes (Daily, 2 shifts, 21 days). Categories: 1.On empty. 2. About half. 3.Full.

    Measure: Adherence to the Nutritional Support System (NSS)

    Time: 5 seconds

    Description: Quantification of the time from when the envelope is added in water, until everything is consumed (Daily, 2 shifts, 21 days). Categories: 1. Less than 15 minutes. 2. More than 15 minutes.

    Measure: Intake time

    Time: 15 minutes

    Description: Quantification of the amount of prepared "NSS" he drink (Daily, 2 shifts, 21 days). Categories: 1.All the preparation. 2.Half. 3.Nothing.

    Measure: Amount of prepared "NSS" he drink

    Time: 15 minutes

    Description: In-person verification of the taking of the floratil pill and observe that they do not vomit it (Daily, 2 shifts, first 6 days). Categories: 1. The pill is taken. 2.The pill is not taken.

    Measure: Taking of the "floratil" pill

    Time: 20 seconds

    Description: Corroborate in person the correct application of the neurobion injection (Daily, evening, first 5 days). Categories: 1. It applies. 2.Not applicable.

    Measure: Neurobion injection

    Time: 1 minute

    Description: Unit of thermal energy, which is equal to the amount of heat needed to raise the temperature of 1 gram of water by 1 degree Celsius. Unit of measurement of the energy content of food that consists of the number of calories that a given weight of food can develop in the tissues, or in the physical work equivalent to them. Calculate the grams that the food has of each macronutrient and multiply it by the energy intake. Based on the Mexican Equivalent Food System. Number in Kcal.

    Measure: Diet calories

    Time: 15 minutes

    Description: Evaluate the amount of trans fat in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

    Measure: Trans fat in the diet

    Time: 2 minutes

    Description: Evaluate the amount of saturated fat in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

    Measure: Saturated fat in the diet.

    Time: 2 minutes

    Description: Evaluate the amount of monounsaturated fats in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

    Measure: Monounsaturated fats in the diet

    Time: 2 minutes

    Description: Evaluate the amount of polyunsaturated fat in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

    Measure: Polyunsaturated fat in the diet

    Time: 2 minutes

    Description: Evaluate the amount of protein of animal origin in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

    Measure: Protein of animal origin in the diet

    Time: 2 minutes

    Description: Evaluate the amount of plant-based protein in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

    Measure: Plant-based protein in the diet

    Time: 2 minutes

    Description: Accurate record of the amount of fluids administered. Evaluate the income of 24 hrs. (Daily, 2 shifts, 21 days). Number in ml.

    Measure: Fluid balance (income)

    Time: 5 minutes

    Description: Accurate record of the amount of liquids eliminated by any means. Evaluate the expenses of 24 hrs. (Daily, 2 shifts, 21 days). Number in ml.

    Measure: Fluid balance (outcome)

    Time: 5 minutes

    Description: Need or desire to eat. Observe the percentage of the tray with food that was ingested (Daily, 2 shifts, 21 days). Categories: 1. 100% ingested. 2.75%. 3.50%. 4.25%.

    Measure: Hungry

    Time: 15 seconds

    Description: Cardiovascular disease risk indicator. Measure with a tape measure with the patient standing, feet together, arms at the sides and the abdomen relaxed, encircling the abdomen at the level of the navel at the midpoint between the last rib and the iliac crest and without pressing, taking an inspiration deep, taking the measurement at the moment of expelling the air.

    Measure: Abdominal circumference

    Time: 1 minute

    Description: It is used to know the nutritional status of the patient. It is obtained by measuring the middle part of the arm with a tape measure, taking as a reference the length between the point of the shoulder (acromion) and the head of the radius (olecranon). Take the circumference of the arm using a tape measure (every 2 days, 2 hours after breakfast, in the morning, for 21 days). Measure in mm.

    Measure: Arm circumference.

    Time: 3 minutes

    Description: It is measured on the midline of the back of the arm (triceps) at 1 cm from the height of the midpoint of the arm. Taking triceps fold measuring tape and caliper (every 2 days, 2 hours after breakfast, morning, for 21 days)). Measure in mm.

    Measure: Tricipital fold

    Time: 3 minutes

    Description: Calculation from arm circumference and triceps fold. Calculate it according to the formula proposed by Frisancho. (every 2 days, 2 hours after breakfast, morning, for 21 days). Measure in mm2.

    Measure: Arm area

    Time: 1 minute

    Description: Set of peculiarities that characterize the individuals of a species, dividing them into male and female, and make possible a reproduction characterized by genetic diversification. Based on an official ID. Categories: 1. Male 2. Female

    Measure: Biological sex

    Time: 30 seconds

    Description: Time elapsed from the birth of a living being to the moment the calculation is made. Based on an official ID. Number between 30 and 75.

    Measure: Age

    Time: 30 seconds

    Description: Sugars attached to the surface of red blood cells, and according to their composition. Evaluate by blood sample. Categories: 1.A, 2. B, 3.AB 4.O.

    Measure: AB0 system

    Time: 2 minutes

    Description: Protein in red blood cells or erythrocytes. Obtaining by blood sample. Categories: 1.Rh (+) 2.Rh (-).

    Measure: Rh factor

    Time: 2 minutes

    Secondary Outcomes

    Description: Record the use of proton pump inhibitors (omeprazole, pantoprazole) (daily, evening, for 21 days). Categories: 1.Not prescribed. 2.Prescribed.

    Measure: Use of proton pump inhibitors

    Time: 5 seconds

    Description: Record the use of obesity medications (orlistat, acarbose, bile acid sequestrants, etc.) (daily, evening, for 21 days). Categories: 1.Not prescribed. 2.Prescribed.

    Measure: Obesity medications

    Time: 5 seconds

    Description: Record the use of antiepileptic drugs (daily, evening, for 21 days). Categories: 1.Not prescribed. 2.Prescribed.

    Measure: Use of antiepileptic drugs

    Time: 5 seconds

    Description: Record the use of oral contraceptives (daily, evening, for 21 days). Categories: 1.Not prescribed. 2.Prescribed.

    Measure: Use of oral contraceptives

    Time: 5 seconds

    Description: Record the use of antimitotics (colchicine) (daily, evening, for 21 days). Categories: 1.Not prescribed. 2.Prescribed.

    Measure: Use of antimitotics

    Time: 5 seconds

    Description: Chemical substance that kills or prevents the growth of certain classes of sensitive microorganisms. Record the antibiotics that are being administered. (daily, evening, for 21 days) Categories: 1.Not used. 2.Use of antibiotics (specify which)

    Measure: Antibiotics

    Time: 5 seconds

    Description: Medicines whose main pharmacological effect is to relieve pain. Record the analgesics that are being administered (daily, evening, for 21 days). Categories: 1.Not used. 2.Use of analgesics (specify which)

    Measure: Analgesics

    Time: 5 seconds

    Description: Drugs with anti-inflammatory and immunosuppressive effect. Record the corticosteroids that are being administered (daily, evening, for 21 days). Categories: 1.Not used. 2.Use of corticosteroids (specify which).

    Measure: Corticosteroids

    Time: 5 seconds

    Description: Substance that causes the elimination of water and electrolytes from the body through urine. Record the diuretics that are being administered (daily, evening, for 21 days). Categories: 1.Not used. 2.Use of diuretics (specify which)

    Measure: Diuretics

    Time: 5 seconds

    Description: Drugs used to lower blood pressure. Record the antihypertensive drugs that are being administered (daily, evening, for 21 days). Categories: 1.Not used. 2.Use of antihypertensives (specify which)

    Measure: Antihypertensive

    Time: 5 seconds

    Description: Endogenous or exogenous substance that interferes with or inhibits blood clotting, creating an antithrombotic or prohemorrhagic state. Record the anticoagulants that are being administered (daily, evening, for 21 days). Categories: 1.Not used. 2.Use of anticoagulants (specify which)

    Measure: Anticoagulants

    Time: 5 seconds

    Description: Medications that attend to a basic pathology and have not been considered in the previous variables. Record the medications that are being administered and have not been named before (daily, evening, for 21 days). Write the medications.

    Measure: Other medications

    Time: 5 seconds

    Description: Disturbance of the normal state of the level of absorption acutely due to a pathological alteration. Record the acute alterations that affect the absorption of nutrients (daily, evening, for 21 days). Categories: 1.None. 2.Intolerance. 3. Allergies 4. Diarrhea 5. Infection or inflammation in any organ of the digestive system.

    Measure: Acute alterations in the absorption of nutrients.

    Time: 5 seconds

    Description: Any alteration in the response to the action of the drug due to the concomitant reaction of another chemical substance. Side effects reported through the clinic and laboratory (daily, evening, for 21 days). Categories: 1.None. 2.Rash. 3.Head or dizziness. 4.Gastrointestinal pain. 5.Other (specify).

    Measure: Drug interactions and adverse effects

    Time: 5 seconds

    Description: Artificial supply of oxygen (O2) in the inspired air; its main objective is tissue oxygenation. Check the quantity of liters that you have pre-written for 24 hours (daily, evening, for 21 days). Number of liters.

    Measure: Oxygen therapy

    Time: 5 seconds

    Description: Attitude or disposition in emotional life. It is not a transitory emotional situation. It is a state, a way of staying, of being, whose duration is prolonged and fades over the rest of the psychic world. Assess the patient's state of mind (daily, evening, for 21 days). Categories: 1.Happy. 2.Relaxed. 3. Alert. 4. Annoying 5. Sad. 6.Tense. 7.Tired. 8.Depressed

    Measure: Mood

    Time: 5 seconds
    14 Operating Under Resilience (OUR) Project: Stress and Emotion Management for Black/African American Women With Hypertension In a Covid--19 Social Distancing Society

    Covid-19 is an additional stressor Black women have to deal with that may interfere with hypertension self-care management. Social connectedness is a source of resilience for Black women to promote mental and physical health. Unfortunately, in the face of the Covid-19 pandemic, social distancing is a challenge further isolating Black women from their networks. How is social connectedness to manage stress and emotional well-being in a social-distancing society for Black women with hypertension? The research team proposed a synchronous web-based version of Enhanced Co-Created Health Education InterventioN (eCo-CHIN) that build the success and best practices derived from the original intervention. A Covid-19 session will be included as a way of helping Black women to maintain resilience and self-care during stressful times. The eCo-CHIN intervention is innovative and timely because the research team are using a synchronous platform preparing Black women on how to deal with Covid-19 while taking care of self. The primary investigator for this pilot study (Dr. Wright) is a Black Early Stage Investigator and former KL2 (career development) awardee. The interdisciplinary research team has the expertise and resources to deliver this Enhanced Co-CHIN intervention.

    NCT04526145
    Conditions
    1. Stress, Psychological
    Interventions
    1. Behavioral: Stress and emotion management
    MeSH:Hypertension Stress, Psychological
    HPO:Hypertension

    Primary Outcomes

    Description: Weekly participant attendance will be recorded as date, month and year.

    Measure: Determine the feasibility of a synchronous web-based health education program, of OUR project.

    Time: 4 weeks

    Description: Investigator generated open-ended questions.

    Measure: Determine the acceptability of a synchronous web-based health education program, of OUR project.

    Time: 1 month

    Description: Weight measured in pounds.

    Measure: Change from baseline at 3 months weight.

    Time: Baseline to 3 months

    Description: Waist circumference measured in inches.

    Measure: Change from baseline at 3 months waist circumference.

    Time: Baseline to 3 months

    Description: Self-blood pressure collection using an automatic home blood pressure monitor systolic and diastolic in mmHg

    Measure: Change from baseline at 3 months blood pressure.

    Time: Baseline to 3 months

    Secondary Outcomes

    Description: Perceived Stress Scale is a 10-item Likert scale questionnaire regarding stress over the past month with higher scores indicating higher levels of stress. Ranges 0-30.

    Measure: Change from baseline stress at 3 months.

    Time: baseline to 3 months

    Description: Difficulties in Emotion Regulation Scale. This measure has 18 items, each measured on a 5-point rating scale. One total score will calculated by summing the individual item responses. Higher scores represent greater perceived difficulties in emotion regulation capabilities.

    Measure: Change from baseline emotional regulation at 3 months.

    Time: baseline to 3 months

    Description: Dietary Approaches to Stop Hypertension Questionnaire (DASH-Q). The DASH Q had 15 items eliciting responses regarding the consumption of DASH diet foods (e.g., fruits, nuts, and vegetables) in the past seven days. Higher score indicates greater DASH knowledge. Range 0-105.

    Measure: Change from baseline dietary approaches to stop hypertension knowledge at 3 months.

    Time: baseline to 3 months

    Description: The Brief Resilience Scale contains 5 questions on a Likert type scale assessing the ability to "bounce back" from stressors. Scores will be summed and higher scores indicate higher resilience.

    Measure: Change from baseline resilience at 3 months.

    Time: baseline to 3 months

    Description: All of Us Program COVID-19 COPE Survey contains items that are not scored on a summary scale, that include social distancing experiences, COVID-19 related symptoms, and COVID-19 related treatment. Descriptive statistics will be used to summarize participant's experiences.

    Measure: Describe participant experience and health during the COVID-19 pandemic.

    Time: Baseline

    Other Outcomes

    Description: The Repeatable Neuropsychiatric Battery (RBANS) will be collected. The RBANS consists of 12 subtests that assess cognitive domains such as Immediate and Delayed Memory, Language, Attention, and Visuospatial/Construction and takes about 30 minutes to administer. A total RBANS sum of index scores will be computed by age.

    Measure: Explore the feasibility of collecting cognitive performance data (processing speed, attention, and executive function) via teleconference.

    Time: baseline and 3 months
    15 Randomized, Double-blind, Placebo-controlled, Multicenter, Multi-arm, Phase II Trial of Novel Agents for the Treatment of Mild to Moderate COVID-19 Positive Outpatients

    This is a randomized, double-blind, placebo-controlled, multi-arm, multicenter, phase II trial design to allow a rapid efficacy and toxicity assessment of potential therapies (camostat mesilate and artemisia annua) immediately after COVID-19 positive testing in mild to moderate disease and high-risk factors such as diabetes, hypertension, and obesity among others.

    NCT04530617
    Conditions
    1. Covid19
    2. Diabetes
    3. Hypertension
    4. Obesity
    Interventions
    1. Drug: Camostat Mesilate
    2. Drug: Artemisia Annua Leaf
    MeSH:Hypertension
    HPO:Hypertension

    Primary Outcomes

    Description: Decrease in a composite outcome of hospitalization and supplemental oxygen use at day 14 between treatment pairs.

    Measure: Rate of hospitalizations and oxygen use

    Time: 14 days
    16 Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic

    This trial is focusing on blood pressure control for patients with high blood pressure (hypertension) during the COVID-19 pandemic when seeing a doctor for advice may be difficult. The study utilises remote consultations by telephone or video conferencing. Patients record blood pressure and data into an electronic diary on their phone which is reviewed in consultations every 2 weeks by a clinician. Medication for this trial is amlodipine as an oral solution which is uptitrated accordingly for patients receiving medication (anticipated 200). 800 patients will be in an observational group recording the same readings and will not receive any medication.

    NCT04559074
    Conditions
    1. Hypertension
    Interventions
    1. Drug: Amlodipine
    MeSH:Hypertension
    HPO:Hypertension

    Primary Outcomes

    Description: The primary objective of the study is to assess precision dosing of amlodipine to deliver reductions in blood pressure in participants with primary hypertension and inadequate BP control by up-titration of amlodipine in 1-2 mg increments.

    Measure: Reductions in blood pressure in participants with primary hypertension and inadequate BP control by up-titration of amlodipine in 1-2 mg increments.

    Time: 3 months

    Secondary Outcomes

    Description: Other clinically significant blood pressure measures which related to difference in measured blood pressure between baseline and EOS

    Measure: Mean change in daily DBP

    Time: 3 months

    Description: Difference between mean changes of blood pressure between interventional and observational cohorts.

    Measure: Difference between mean changes of blood pressure

    Time: 3 months

    Description: Reports of side effects using digital diary

    Measure: Collect data on tolerability / side effects

    Time: 3 months
    17 Comparison of Physical Activity Levels and Disease Attitudes of Hypertensive and Healthy Individuals Under Social Isolation During the COVID-19 Pandemic

    COVID-19 is an emergency situation which broke out from China in 2020. Health commitees and goverment set some rules and limit people's freedom to leave from their houses and it is called as 'social isolation'.Staying at home and disease bring about sedentary lifestyle, anxiety and depression and changed eating habits of all person. Hypertension is an important cardiovasculary risk factor and physical activity, stress managament are very important for disease control. In that study we aimed to assess hypertensive and healthy person's anxiety level, physical activity and qualit of life level during COVID-19 social isolation.

    NCT04583345
    Conditions
    1. Hypertension
    2. Social Isolation
    3. COVID
    Interventions
    1. Behavioral: Questionnaires
    MeSH:Hypertension
    HPO:Hypertension

    Primary Outcomes

    Description: Physical activity level assessed with International Physical Activity Questionnaire (IPAQ) long version. IPAQ long version asks work-related, transport, domestic and recreational physical activities. It categorizes physical activities vigorous, moderate and walking. It uses frequency and duration of activities. Every physical activity category has a point and better physical activity level is related with higher IPAQ scores.

    Measure: Physical Activity

    Time: 2 months

    Secondary Outcomes

    Description: It will assess with Short form 36 questionnaire. It assesses quality of life and it contains different parameters for example body function, pain, physical and mental health etc. Each subscale is evaluated between 0-100 points. A higher score indicates the better health.

    Measure: Quality of Life Assesment

    Time: 2 months

    Description: Healthy lifestyle behavior will asssess with Healthy Life Style Behavior Scale. The reliability and validity of the scale has been studied in Turkey. The lowest score that can be obtained from these three sub-dimensions is 26 and the highest score that can be obtained is 104.Positivite healthy lifestyles related with higher scores.

    Measure: Evaluation of Individuals Healthy Lifestyle Behaviors

    Time: 2 months

    Description: Hospital Anxiety and Depression Scale (HADS) will use.The HADS contains fourteen item. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains.

    Measure: Anxiety and Depression Level

    Time: 2 months
    18 Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV

    Social distancing measures put in place to combat the COVID-19 disease pandemic may increase social isolation and impact cardiovascular disease prevention behaviors among people living with HIV (PLWH). This study builds on a previously developed nurse-led intervention to improve blood pressure and cholesterol care for PLWH. The investigators will adapt the intervention to be administered virtually in order to facilitate cardiovascular prevention care within the US health care system which has sustained long-term changes as a result of the COVID-19 pandemic. The implementation and effectiveness of the intervention will be tested in a 12-month single arm intervention study.

    NCT04661813
    Conditions
    1. HIV-1-infection
    2. Hypertension
    Interventions
    1. Other: EXTRA-CVD Virtual Care
    MeSH:Hypertension
    HPO:Hypertension

    Primary Outcomes

    Description: Monitored continuously during study enrollment period

    Measure: Proportion of eligible participants who agree to participate

    Time: Through completion of study enrollment, an average of 9 months

    Description: Repeated measures analysis across 4 time-points (0-, 4-, 8-, and 12-months)

    Measure: Average of home blood pressure values assessed over a 2-week period at 0-, 4-, 8-, and 12-months.

    Time: 12 months

    Description: Repeated measures analysis across 4 time-points (0-, 4-, 8-, and 12-months)

    Measure: Number of days with at least 1 home blood pressure measurement assessed over a 2-week period at 0-, 4-, 8-, and 12-months.

    Time: 12 months

    HPO Nodes


    HP:0000822: Hypertension
    Genes 424
    MAT2A WT1 LMNA HGD FN1 TRNL1 SERPINA6 YY1AP1 TRNK BBIP1 GTF2IRD1 TRNC KCNJ5 CLCN2 MGP TGFBR2 BBS1 CYP11B2 RET ARVCF KCNJ5 EGFR OSGEP SH2B3 TRNS2 SLC2A10 NKX2-5 LMNA RREB1 IFT172 LZTFL1 ND1 FBN1 FMO3 HLA-DPA1 GUCY1A1 APOB SCNN1G CEP164 BBS10 FUZ SDHB MUC1 REST ABCC6 TTC8 CLIP2 H19 ELN FGFR2 GATA5 PKD1 NF1 NPHP1 KCTD1 WNK4 HIRA GP1BB GNAS IRF5 EDA2R LMX1B NFU1 PLIN1 MEN1 SEC24C ELN GNAS COL3A1 NPHP1 SLC37A4 ERCC8 HLA-DPB1 NOTCH1 CFHR1 THSD1 SDCCAG8 DLST PKHD1 PPOX ACTN4 DNMT3A NOD2 SCNN1B C8ORF37 ECE1 XYLT1 ACTA2 GDNF CTLA4 PAM16 EPAS1 BBS4 ARL6 CCR6 DNAJB11 CDH23 ENPP1 WT1 DIS3L2 PKD2 MFAP5 GLA PKD2 NPHP1 TRNW NF1 IFT27 BANF1 CFI LMNA WNK1 WT1 ARHGAP31 SMARCAL1 FGFR2 STAT2 ACVRL1 CEP290 ADA2 NF1 SDHAF2 ENPP1 PRKAR1A IQCB1 PRTN3 TET2 SMAD6 XYLT2 NOD2 SDHD HPSE2 MYH11 SDHD COX1 PDE8B CAV1 C3 SMAD4 SCNN1G ELP1 USP8 EXT2 USP8 KIF1B SLC25A11 FBN1 CBS WDPCP BBS9 BRCC3 ACAT1 SPRY2 TRNF STAT1 SUGCT ELP1 SCNN1A GPR101 PPARG ZMPSTE24 MAX LRIG2 TRNS1 GJA1 ERCC8 BSCL2 CYP11B1 NPHP3 TRNE FIG4 CCND1 CD2AP KCTD1 TRAF3IP1 TRNK GBA TGFB2 CYTB HMBS GLA TRIM32 EDA SDHC TNFRSF11A LDLRAP1 MMP2 XPNPEP3 PKD1 KIF1B ABCC6 TRIM28 SDHB SDCCAG8 ALMS1 MAFB FN1 PTPN22 ACP5 ERCC4 LEMD3 CYP11B1 BBS7 SDHB LDLR SCNN1A NPHP4 KRT18 HSD11B2 CDKN1B CCN2 CUL3 GANAB PDE3A VANGL1 TSC2 ACTA2 PCSK9 CEP19 CFB SMAD4 MTTP COL4A5 LYZ FOXE3 IDS PRKG1 SLC37A4 PHF21A GUCY1A1 B2M RET INVS KCNJ5 PPARG WRN PLIN1 BMPR2 CDKN2C MMP14 VHL POU6F2 ELN COL4A3 CPOX ABCB6 CDH23 LMX1B THBD KIF1B SLC2A10 PDE11A JMJD1C CYP17A1 TRNK TBX1 IL12B COQ7 TBL2 TBX1 WDR19 LRP6 FMR1 SDHD CORIN RFC2 CACNA1H CYP11B1 MKKS ADA2 LIMK1 NOTCH3 MKS1 FLT1 BBS1 CACNA1D YY1AP1 CDKN2B ND6 LMNA MLX VAC14 PKHD1 TRIP13 PDE11A MEF2A IDS TRIM28 NDUFAF6 NOS3 TRNQ SDHB SDHC STOX1 SMAD3 ALX4 APRT LOX OFD1 IDUA TMEM127 COL3A1 AIP FBN1 LMNA CFH WT1 VHL NR3C1 CYP17A1 TSC1 ALMS1 SMAD4 POU3F4 FGA HMBS TP53 HBB ARMC5 BRCA2 SDHA CACNA1D ABCG5 RET UFD1 TREX1 NOTCH2 ABCC6 G6PC1 ARMC5 SCNN1B CCDC28B GTF2I JAK2 KLHL3 BBS5 MYH7 ERCC6 APOA1 TRNV TMEM127 TGFBR1 GNAS FBN1 ARL6 GCH1 COX2 MDH2 NFIX OFD1 AIP COL4A3 WDR35 ENG MAX CFHR3 TMEM70 NSMCE2 LARS2 LEMD3 ND5 CYP21A2 NR3C1 DZIP1L BNC2 VHL BICC1 ERCC6 PRKACA MC4R PRKACA ADA2 CYP11B1 INF2 HLA-DRB1 MYLK TGFB3 MTRR MYMK POR COL4A4 JAK2 SDHD SCN2B CEP290 ITGA8 FH DYRK1B TRPC6 HLA-B PRKAR1A MLXIPL BBS12 MDM2 MPL TMEM237 VHL BBS2 PDE3A NR3C2 KRT8 GPC3 PRKAR1A BAZ1B ERCC4 VHL TGFBR3 CDKN1A COMT WT1 SLC25A11 RET COX3 AIP ABCG8 HSD11B2 GANAB TMEM67 CD46 ADAMTSL4 TNFRSF11B ANGPTL6 INVS TRNL1

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0000822: Hypertension
    Genes 424
    MAT2A WT1 LMNA HGD FN1 TRNL1 SERPINA6 YY1AP1 TRNK BBIP1 GTF2IRD1 TRNC KCNJ5 CLCN2 MGP TGFBR2 BBS1 CYP11B2 RET ARVCF KCNJ5 EGFR OSGEP SH2B3 TRNS2 SLC2A10 NKX2-5 LMNA RREB1 IFT172 LZTFL1 ND1 FBN1 FMO3 HLA-DPA1 GUCY1A1 APOB SCNN1G CEP164 BBS10 FUZ SDHB MUC1 REST ABCC6 TTC8 CLIP2 H19 ELN FGFR2 GATA5 PKD1 NF1 NPHP1 KCTD1 WNK4 HIRA GP1BB GNAS IRF5 EDA2R LMX1B NFU1 PLIN1 MEN1 SEC24C ELN GNAS COL3A1 NPHP1 SLC37A4 ERCC8 HLA-DPB1 NOTCH1 CFHR1 THSD1 SDCCAG8 DLST PKHD1 PPOX ACTN4 DNMT3A NOD2 SCNN1B C8ORF37 ECE1 XYLT1 ACTA2 GDNF CTLA4 PAM16 EPAS1 BBS4 ARL6 CCR6 DNAJB11 CDH23 ENPP1 WT1 DIS3L2 PKD2 MFAP5 GLA PKD2 NPHP1 TRNW NF1 IFT27 BANF1 CFI LMNA WNK1 WT1 ARHGAP31 SMARCAL1 FGFR2 STAT2 ACVRL1 CEP290 ADA2 NF1 SDHAF2 ENPP1 PRKAR1A IQCB1 PRTN3 TET2 SMAD6 XYLT2 NOD2 SDHD HPSE2 MYH11 SDHD COX1 PDE8B CAV1 C3 SMAD4 SCNN1G ELP1 USP8 EXT2 USP8 KIF1B SLC25A11 FBN1 CBS WDPCP BBS9 BRCC3 ACAT1 SPRY2 TRNF STAT1 SUGCT ELP1 SCNN1A GPR101 PPARG ZMPSTE24 MAX LRIG2 TRNS1 GJA1 ERCC8 BSCL2 CYP11B1 NPHP3 TRNE FIG4 CCND1 CD2AP KCTD1 TRAF3IP1 TRNK GBA TGFB2 CYTB HMBS GLA TRIM32 EDA SDHC TNFRSF11A LDLRAP1 MMP2 XPNPEP3 PKD1 KIF1B ABCC6 TRIM28 SDHB SDCCAG8 ALMS1 MAFB FN1 PTPN22 ACP5 ERCC4 LEMD3 CYP11B1 BBS7 SDHB LDLR SCNN1A NPHP4 KRT18 HSD11B2 CDKN1B CCN2 CUL3 GANAB PDE3A VANGL1 TSC2 ACTA2 PCSK9 CEP19 CFB SMAD4 MTTP COL4A5 LYZ FOXE3 IDS PRKG1 SLC37A4 PHF21A GUCY1A1 B2M RET INVS KCNJ5 PPARG WRN PLIN1 BMPR2 CDKN2C MMP14 VHL POU6F2 ELN COL4A3 CPOX ABCB6 CDH23 LMX1B THBD KIF1B SLC2A10 PDE11A JMJD1C CYP17A1 TRNK TBX1 IL12B COQ7 TBL2 TBX1 WDR19 LRP6 FMR1 SDHD CORIN RFC2 CACNA1H CYP11B1 MKKS ADA2 LIMK1 NOTCH3 MKS1 FLT1 BBS1 CACNA1D YY1AP1 CDKN2B ND6 LMNA MLX VAC14 PKHD1 TRIP13 PDE11A MEF2A IDS TRIM28 NDUFAF6 NOS3 TRNQ SDHB SDHC STOX1 SMAD3 ALX4 APRT LOX OFD1 IDUA TMEM127 COL3A1 AIP FBN1 LMNA CFH WT1 VHL NR3C1 CYP17A1 TSC1 ALMS1 SMAD4 POU3F4 FGA HMBS TP53 HBB ARMC5 BRCA2 SDHA CACNA1D ABCG5 RET UFD1 TREX1 NOTCH2 ABCC6 G6PC1 ARMC5 SCNN1B CCDC28B GTF2I JAK2 KLHL3 BBS5 MYH7 ERCC6 APOA1 TRNV TMEM127 TGFBR1 GNAS FBN1 ARL6 GCH1 COX2 MDH2 NFIX OFD1 AIP COL4A3 WDR35 ENG MAX CFHR3 TMEM70 NSMCE2 LARS2 LEMD3 ND5 CYP21A2 NR3C1 DZIP1L BNC2 VHL BICC1 ERCC6 PRKACA MC4R PRKACA ADA2 CYP11B1 INF2 HLA-DRB1 MYLK TGFB3 MTRR MYMK POR COL4A4 JAK2 SDHD SCN2B CEP290 ITGA8 FH DYRK1B TRPC6 HLA-B PRKAR1A MLXIPL BBS12 MDM2 MPL TMEM237 VHL BBS2 PDE3A NR3C2 KRT8 GPC3 PRKAR1A BAZ1B ERCC4 VHL TGFBR3 CDKN1A COMT WT1 SLC25A11 RET COX3 AIP ABCG8 HSD11B2 GANAB TMEM67 CD46 ADAMTSL4 TNFRSF11B ANGPTL6 INVS TRNL1

    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook